
Ayman J Hammoudeh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9546184/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment adherence and quality of life in patients on antihypertensive medications in a Middle Eastern population: adherence. Vascular Health and Risk Management, 2016, Volume 12, 407-413.	2.3	32
2	Outcomes of middle eastern patients undergoing percutaneous coronary intervention: The primary analysis of the First Jordanian PCI Registry. Heart Views, 2017, 18, 3.	0.2	12
3	Incidence and prognosis of stent thrombosis following percutaneous coronary intervention in Middle Eastern patients: The First Jordanian Percutaneous Coronary Intervention Registry (JoPCR1). Annals of Saudi Medicine, 2016, 36, 17-22.	1.1	9
4	Cardiovascular risk factors in Middle Eastern patients undergoing percutaneous coronary intervention: Results from the first Jordanian percutaneous coronary intervention study. Journal of the Saudi Heart Association, 2017, 29, 195-202.	0.4	9
5	Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. International Journal of Vascular Medicine, 2021, 2021, 1-9.	1.0	9
6	Short- and long-term outcomes in Middle Eastern diabetic patients after percutaneous coronary intervention: results from The First Jordanian PCI Registry (JoPCR1). Diabetology International, 2017, 8, 30-38.	1.4	5
7	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. European Cardiology Review, 2021, 16, e43.	2.2	5
8	Blood pressure control in treated hypertensive Middle Eastern patients: a post hoc analysis based on JNC8 definitions. Vascular Health and Risk Management, 2019, Volume 15, 35-46.	2.3	4
9	Smoking Cessation in the Middle East after Percutaneous Coronary Intervention. Results from the First Jordanian Percutaneous Coronary Intervention Registry (JoPCR1). World Journal of Cardiovascular Diseases, 2016, 06, 202-210.	0.2	4
10	One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. International Journal of Vascular Medicine, 2022, 2022, 1-8.	1.0	3
11	Age and Gender-Based Coronary Artery Calcium Scores in a Middle Eastern Population. Cardiovascular Imaging Asia, 2021, 5, 37.	0.1	2
12	Prevalence, Epidemiological Characteristics, and Pharmacotherapy of Coronary Artery Disease among Patients with Atrial Fibrillation: Data from Jo-Fib Study. Medicina (Lithuania), 2021, 57, 605.	2.0	2
13	The Impact of Coexistence of Smoking and Diabetes on the Coronary Artery Severity and Outcomes following Percutaneous Coronary Intervention: Results from the 1ST Jordanian PCI Registry. International Journal of Vascular Medicine, 2020, 2020, 1-7.	1.0	1
14	Clinical Outcomes and Cardiovascular-Related Events in Young Diabetic Patients with Acute Coronary Syndrome. Vascular Health and Risk Management, 2022, Volume 18, 55-60.	2.3	1
15	Demographics and Risk Profile of Elderly Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. Vascular Health and Risk Management, 2022, Volume 18, 289-295.	2.3	1
16	Incidence and impact on prognosis of heart failure in Middle Eastern patients undergoing percutaneous coronary interventions. Asian Journal of Medical Sciences, 2017, 8, 20-28.	0.1	0
17	The participation of Arab women in randomised clinical trials for cardiovascular diseases. International Journal of Clinical Practice, 2021, 75, e14612.	1.7	Ο
18	ls there a Concordance between CHA2DS2 VASc and HAS-BLED Scores in Middle Eastern Patients with Nonvalvular AF? Analysis of the Jordan Atrial Fibrillation (JoFib) Study. Open Cardiovascular Medicine Journal, 2022, 16, .	0.3	0